Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients

Yves Lévy, Rodolphe Thiébaut, Matthieu Montès, Christine Lacabaratz, Louis Sloan, Sophie Pérusat, Carson Harrod, Céline Boucherie, Sandy Zurawski, Laura Richert, Geneviève Chêne, Jacques Banchereau, Karolina PaluckaRetrovirology 2012 · DOI

Abstract

The DALIA trial investigated the efficacy of a therapeutic vaccine using autologous dendritic cells (DCs) primed with HIV-1 lipopeptides. The study demonstrated that this approach significantly enhances the breadth and polyfunctionality of the T cell response in HIV-infected individuals. Crucially, the quality of this immune response—specifically the induction of polyfunctional CD4+ T cells—correlated with improved control of peak viral load following the cessation of antiretroviral therapy.

Introduction

Highly Active Antiretroviral Therapy (HAART) is highly effective at suppressing HIV replication but does not eliminate the virus. HIV persists in latent reservoirs, and treatment interruption almost invariably leads to a rapid viral rebound. A major goal in HIV research is the development of a therapeutic vaccine that can "train" the patient's immune system to recognize and control the virus without lifelong drug dependency. This study explores a dendritic cell-based vaccine strategy, utilizing these "sentinel" cells to present HIV-1 lipopeptides and elicit a robust, protective immune response.

Methods

The DALIA trial was a proof-of-concept study involving 19 HIV-positive patients who were stable on HAART, with CD4 counts exceeding 500 cells/mm³ and undetectable viral loads.

Vaccination Phase

Participants received four doses of a personalized vaccine at weeks 0, 4, 8, and 12. The vaccine consisted of IFN-$α$ dendritic cells generated ex-vivo and loaded with five HIV-1 lipopeptides.

Analytical Treatment Interruption (ATI)

At week 24, patients underwent an Analytical Treatment Interruption (ATI), pausing their HAART medication to evaluate the immune system's ability to control the returning virus. Monitoring continued through week 48, focusing on viral load (VL) dynamics and CD4 counts.

Immunological Assays

Researchers utilized IFN-$γ$ ELISPOT, intracellular cytokine staining, and multiplex analysis to measure the "breadth" (the number of viral components recognized) and "polyfunctionality" (the ability of single cells to produce multiple defensive signals, such as IFN-$γ$, TNF-$α$, and IL-2) of the T cell response.

Results

Safety and Immunogenicity

The vaccine was well-tolerated by all 19 participants. Immunological monitoring showed a dramatic increase in the frequency of HIV-specific immune cells, jumping from a median of 186 SFU/10⁶ PBMC at baseline to 1878 SFU/10⁶ PBMC at week 48.

Breadth and Quality of Response

The vaccine successfully expanded the breadth of the immune response. While patients recognized a median of only one HIV peptide pool at baseline, this increased to six post-vaccination. Furthermore, the researchers identified a significant increase in polyfunctional CD4+ ($P=0.002$) and CD8+ ($P=0.005$) T cells.

Correlation with Viral Control

While all patients experienced a viral rebound after stopping HAART (median 14 days), the intensity of the rebound was linked to the vaccine's performance. A robust inverse correlation was found between the peak viral load and the percentage of polyfunctional CD4+ T cells ($r = -0.63, FDR = 0.007$). Additionally, higher production of specific cytokines—IL-2, IFN-$γ$, IL-21, and IL-13—was associated with lower viral peaks.

Discussion

The DALIA trial highlights that the quality of the immune response is more critical than the mere quantity of immune cells. The induction of polyfunctional T cells capable of multi-cytokine production appears to be a key biomarker for viral control.

However, several limitations remain. The small cohort size (n=19) means these findings require validation in larger trials. Additionally, while the vaccine reduced the peak of the viral rebound, it did not prevent the rebound entirely or achieve a "functional cure" where the virus remains undetectable without medication. Eight patients experienced CD4 count drops below safety thresholds, and three required the resumption of HAART during the study.

Conclusion

Vaccination with IFN-$α$ dendritic cells loaded with HIV-1 lipopeptides is a promising strategy for eliciting broad, polyfunctional T cell immunity. This study provides a roadmap for the types of immune signatures required for viral control and suggests that future therapeutic efforts should focus on enhancing the polyfunctional quality of the T cell response.

Summary updated

Abstract

International audience
BibTeX
@inproceedings{levy2012vaccination,
  author = {Yves Lévy and Rodolphe Thiébaut and Matthieu Montès and Christine Lacabaratz and Louis Sloan and Sophie Pérusat and Carson Harrod and Céline Boucherie and Sandy Zurawski and Laura Richert and Geneviève Chêne and Jacques Banchereau and Karolina Palucka},
  title = {{Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients}},
  booktitle = {Retrovirology},
  year = {2012},
  doi = {10.1186/1742-4690-9-s2-p328},
}
Figure